Expert Interview
Evaluating Viridian Therapeutics’ SubQ Elegrobart and Amgen's SubQ TEPEZZA® (teprotumumab) for the Treatment of Thyroid Eye Disease
Ticker(s): VRDN, AMGNInstitution: Houston Methodist & Mann Eye Institute
- Oculoplastic Surgeon at Houston Methodist & Mann Eye Institute
- Sees 2-3 patients with TED per week and manages at least 50 annually
- Involved in multiple TED trials in his career including: ASCEND GO-2: Study of batoclimab (RVT-1401), Phase 2/3 clinical trials for Tepezza, and currently works on research in IGF-1R pathways.
Roughly how many patients with Thyroid Eye Disease do you currently manage?
Added By: allan_adminHow big of a difference will a SubQ treatment for TED make?
Added By: allan_adminHow do you view the administrative dropouts in the Q4W arm's impact on efficacy in REVEAL-1?
Added By: user51c2ad2aAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
